VivoSeq
Oncology

Solid Tumors

11

Pipeline Programs↗

161

Active Trials↗

121

Companies Involved↗

Solid Tumors is an emerging landscape with 11 programs across 121 companies. The most active players are Boehringer Ingelheim, Merck & Co., AstraZeneca. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

59/100

Mech. Concentration

20/100

Completion Rate

68/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 1Merck & Co. logo

Merck & Co.

4 programs

Phase 3AstraZeneca logo

AstraZeneca

1 program

Phase 3Novartis logo

Novartis

1 program

Phase 3Eisai logo

Eisai

1 program

Phase 3Roche logo

Roche

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

73%

Small molecule

8 of 11 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody218%Protein / enzyme19%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 93% of 14 pipeline programs.

Analysis

Trial Status

512

clinical trials

Completed214 · 42%
Recruiting97 · 19%
Terminated76 · 15%
Active, not recruiting44 · 9%
Unknown status34 · 7%
Not yet recruiting20 · 4%
Other27 · 5%

Clinical Trials

Trial Activity

512 trials

A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors
Recruiting·SShouyao Holdings (Beijing) Co. LTD·Phase 1·NCT06037317·38 enrolled
Tumor Vaccines for Solid Tumors
Recruiting·HHuashan Hospital·N/A·NCT06102837·340 enrolled
A Study of CRD3874-SI in People With Solid Tumors
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06021626·72 enrolled
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Recruiting·AALX Oncology Inc.·Phase 1·NCT07085091·170 enrolled
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Recruiting·Novartis logoNovartis·Phase 1·NCT07006727·116 enrolled
Sapu003 in Advanced mTOR-sensitive Solid Tumors
Recruiting·SSAPU NANO (US) LLC·Phase 1·NCT07369505·27 enrolled
PD-L1 Specific 68Ga-THP-PD-L1-3 Probe for PET Imaging in Solid Tumors
Recruiting·—·N/A·NCT06383598·50 enrolled
Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06047977·30 enrolled
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
Recruiting·TTrethera·Phase 1·NCT05055609·94 enrolled
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 1·NCT06963281·285 enrolled
Intravital Microscopy in Human Solid Tumors
Recruiting·MMayo Clinic·N/A·NCT03823144·85 enrolled
PET [89Zr]DFO-starPEG in Solid Tumors
Recruiting·RRobert Flavell, MD, PhD·Phase 1·NCT06894745·13 enrolled
Anti-cancer DC Cell Vaccination to Treat Solid Tumors
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT06477614·60 enrolled
KSX01-TCRT Injection Project in Solid Tumors
Recruiting·TTCRx Therapeutics Co.Ltd·Phase 1·NCT05811975·50 enrolled
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
Recruiting·—·N/A·NCT06509490·9 enrolled
Page 1 of 35

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)